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30, D-52057 Aachen, GermanyStenoses and thromboses of dialysis grafts and fistulae are common problems in patients with end stage renal disease (ESRD).
Timely recognition and treatment of access-related complications are essential to achieve long-term access function.
Minimally invasive percutaneous interventions are techniques of growing importance for the interventional community.
While stenoses can typically be treated by balloon angioplasty (PTA), thrombotic lesions may necessitate the combination of
mechanical devices and/or thrombolytic agents with ancillary PTA. In this article, interventional treatments for the failing
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Dysfunction of arteriovenous fistulae and grafts
occurs frequently in haemodialysis patients and
contributes significantly to morbidity and hospitaliz-
ation in the dialysis population.1 The number of
patients with end-stage renal disease has risen steadily
to reach over 420,000 in the United States alone,2 so
that the choice of a suitable method to preserve
vascular access is of increasing significance for the
patients and their physicians. Over the last decade
vascular access complications have been increasingly
approached on a multidisciplinary basis. It must be
emphasized that early diagnosis and treatment of
access-related complications are vital to achieve long-
term access function. Nowadays, dialysis centres often
request percutaneous interventions in the manage-
ment of AV-access-related problems. Existing percu-
taneous treatment indications and algorithms for
stenosed and/or thrombosed dialysis grafts and
fistulae are described in this article.AV Fistula Stenosis
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tion. In radiocephalic AV fistulas, 55–75% of stenoses
are located close to the AV anastomosis and w25% in
the outflow tract.3,4 In brachiocephalic and/or basilic
AV fistulas the typical location (55%) is at the junction
of the cephalic with the subclavian vein and the basilic
with the axillary vein, respectively.3 An arterial inflow
stenosis O2 cm from the anastomosis is uncommon,
but may endanger flow into the AV fistula.
To visualize a stenosis, angiography is performed
by either retrograde puncture of the brachial artery for
anastomotic problems, or by direct antegrade punc-
ture of the postanastomotic vein if an outflow problem
has occurred.5
Primary interventional treatment by PTA is indi-
cated in stenoses of the anastomotic area located in the
upper forearm and in the upper arm. PTA is also
possible in stenoses of the anastomotic area located in
the lower forearm as an alternative to surgical
treatment (Fig. 1). Success rates are greater than 90%
with 1-year primary patency rates of up to 51%.4,6
Steal syndrome and hand ischaemia are rare
potential complications after treatment of anastomotic
stenoses in upper arm fistulas.
In the case of stenosis of the outflow tract or at the
junction of the superficial vein with the deep venous
system PTA again is the first treatment option.7
In general, the stenosis is negotiated with a
hydrophilic coated, 0.035-in. guidewire, followed by
the balloon catheter passed over the guidewire.Eur J Vasc Endovasc Surg 32, 84–89 (2006)
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Fig. 1. Angiogram demonstrates postanastomotic stenoses with pearl-string appearance (a). Notice the distinct morphologic
and haemodynamic improvement after balloon angioplasty (b).
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philic, catheter may be necessary to overcome tortuous
vessel segments.
Careful dilatation with a pressure of about 10 atm
for up to 1–2 min is recommended, which may be
repeated.
Some stenoses cannot be dilated sufficiently by
conventional balloon angioplasty. These stenoses can
be treated with cutting balloons.8 In our experience
even stenoses longer than 5 cm can be approached
radiologically, although graft interposition9 is an
option.
A restenosis can be treated radiologically, with or
without a stent, or surgically5 depending upon the
individual situation and the potential invasiveness of
the surgical treatment.
Despite the complete expansion of the PTA balloon
(without a waist) of sufficient diameter, the dilated
vessel wall may collapse immediately after removal of
the balloon. This elastic recoil can be treated with stent
implantation, especially in central veins.10 Stent
placement in the needling areas of forearm fistulas
should be reserved for acute PTA-induced ruptures
not controllable by prolonged balloon inflation.AV Fistula Thrombosis
The duration, location and extent of AV fistula
thrombosis as well as the type of access are important
determinants of treatment outcome. Fistula thrombo-
sis should be treated within 48 h whenever possible.
Timely declotting allows immediate use without needfor central venous access. Although comparative
studies are lacking, the available literature strongly
suggests that thrombosed autogenous AV fistulas
should preferably be treated by interventional radi-
ology. The only exception may be forearm AV fistulas
that have thrombosed due to anastomotic stenosis. It is
likely that in such cases, creation of a new proximal
anastomosis will provide good results although no
surgical series has demonstrated this thus far.
Interventional thrombolysis can be performed
mechanically or pharmacomechanically. A short-
segment thrombosis can be simply treated with
balloon angioplasty alone; however, an extensive
thrombosis requires the combination of mechanical
devices and/or thrombolytic agents with consecutive
balloon angioplasty.
Poulain et al. combined a local low dose infusion of
urokinase with PTA and thromboaspiration to achieve
a 12-month overall patency in 14 native fistulas of
approximately 90%.11 Zaleski et al. reported on 17
patients with complete thrombosis of their Brescia–
Cimino fistulas, whichwere treated by angioplasty and
urokinase infusion.12 Procedural success was 82%with
primary, primary assisted, and secondarypatency rates
at 12 months of 71, 93, and 100%, respectively.
Twenty of 24 patients (83%) with occluded Brescia–
Cimino fistulas were successfully recanalized by
Overbosch et al. using the Hydrolyser catheter.13
Median assisted patency was 34 weeks and was
significantly shorter in fistulas than in PTFE grafts
(pZ0.002).
Turmel-Rodrigues et al. described an 81% initial
success rate using thromboaspiration and PTA in 16Eur J Vasc Endovasc Surg Vol 32, July 2006
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Fig. 2.AV fistula thrombosis treatment (nZ81). Graph of life-
table analysis depicting Aachen University Hospital primary
and cumulative patency rates.
P. Haage and R. W. Gu¨nther86patients.14 An 81% secondary patency at 1 year was
reported.
Liang et al. reported a success rate of 93% and a
primary patency rate at 1 year of 70%.15
In our department, we have had a technical success
rate of almost 90% in 81 native fistula procedures with
a combination of PTA and mechanical thrombectomy
devices (amplatz mechanical thrombectomy device
and hydrolyser catheter). The primary and overall
fistula patency was 27 and 51% at 1 year, respectively,
pinpointing the efficacy of percutaneous thrombosis
treatment strategies16 (Fig. 2).
These results show that initial percutaneous inter-
ventions in occluded native arteriovenous fistulas are
very effective in the early treatment of the recently
occluded dialysis access with good success rates and
satisfactory primary and long-term patency rates
comparable to those of surgical thrombectomy. How-
ever when percutaneous thrombolysis is feasible,
surgical revision should be reserved for failures of
percutaneous techniques. The choice of the appro-
priate percutaneous approach will depend on the size
and location of the thrombus detected by angiography,
while the choice of device depends on the experience
of the centre with the respective modality.Graft Stenosis
A reduction of O50% of the lumen diameter together
with significant flow decline is a recommended
indication for treatment in graft stenosis.17 As in AV
fistulas, most arterial inflow stenoses can be effectively
treated by PTA.18 Success rates of 98% have been
observed by some groups.19 The procedural approach
is essentially similar to the management of fistulaEur J Vasc Endovasc Surg Vol 32, July 2006stenosis. A stenosis of the arterial anastomosis itself
can be dilated, provided only the afferent artery and
the graft is affected but the efferent artery is not
stenosed. If there is an additional stenosis of the
efferent artery, angioplasty of the anastomosis alone
will enhance graft flow with the risk of peripheral
ischemia due to reduced peripheral arterial perfusion.
In these patients, percutaneous dilatation of the
efferent artery may solve the problem.
Intra-graft (or mid-graft) stenoses are found in the
cannulation segment of access grafts. They result from
excessive in-growth of fibrous tissue through puncture
holes. These stenoses can be treated by PTA,20 or
alternatively by graft curettage21 and segmental graft
replacement.
The most common cause for access graft dysfunc-
tion is venous anastomotic stenosis.22 Since access
grafts should be reserved for patients with exhausted
peripheral veins, vessel saving procedures like PTA
should be preferred to graft extensions to more central
vein segments, although the latter may have superior
patency rates.
When PTA repeatedly fails, additional stent implan-
tation should be considered.23
When recurrent stent obstruction occurs, graft
extension is still possible.Graft Thrombosis
As with AV fistula occlusion, graft thrombosis should
be treated without delay and within 48 h, at least
before the next dialysis session. A compact ‘arterial
plug’ is invariably seen. Mature thrombi older than
5 days are often fixed to the vessel wall beyond the
venous anastomosis, rendering surgical extraction
more difficult. In grafts, this is less of a problem for
the interventional radiologist.
PTFE graft thrombosis can be approached using a
wide array of percutaneous techniques including
combinations of thromboaspiration, thrombolytic
agents such as tissue plasminogen activator (tPA),
mechanical thrombectomy and mechanical thrombect-
omy devices. Turmel-Rodrigues et al. found higher
patency rates after radiological intervention with a 6
month primary patency rate of 32% in thrombosed
grafts.3 The results of the treatment of thrombosis and
associated stenosis in synthetic grafts have been
summarized by Aruny et al.24 Clinical success rates
for thrombolysis or mechanical thrombectomy range
from 75 to 94% with primary patencies of 18–39% at 6
months. Reported 6- and 12-month secondary paten-
cies for thrombolysis range from 62 to 80 and 57 to
69%, respectively.
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Fig. 3. Aachen University Hospital primary and cumulative
central venous stent patency rates (nZ50).
Interventional Access Maintanence 87Trerotola et al. demonstrated a 95% technical
success with a 3-month primary patency of 39%
using the Arrow-Trerotola percutaneous thrombolytic
device.25
Comparing different mechanical devices for
percutaneous thrombolysis, Smits et al. concluded,
that ‘the treatment of the underlying stenoses was
the only predictive value for graft patency’.26 Each
centre should therefore choose the technique accord-
ing to their expertise. Whichever technique is used,
it is important to perform thrombolysis rapidly to
avoid the need for a temporary catheter and as an
outpatient procedure to decrease costs, whenever
possible.
The involvement of large veins, e.g. the brachial
vein, to a large extent complicates management in
fistula and graft patients and is an additional
important feature determining technical success.
Durable access function depends on various factors
such as cannulation trauma, tendency for restenosis,
hypercoagulability, and the frequency of
reobstruction.27AV access aneurysm
In long segment fistula aneurysms percutaneous
interventional treatment with implantation of a
covered stent is possible as an alternative to surgery,
however, deployment at the needling area must be
avoided.28 Anastomotic aneurysms and large aneur-
ysms with a significant thrombus-load should pre-
ferably be treated surgically.29 False aneurysmsmay be
treated by thrombin injection under ultrasound
guidance. Since aneurysm expansion is due to
increased intra-access pressure usually as a result of
venous outflow obstruction, local treatment always
should go along with outflow repair by PTA and/or
thrombectomy/thrombolysis.Central venous obstruction
Swelling of the access arm is the most significant
clinical symptom of central venous obstruction.30 The
superficial veins may become prominent due to
collateral flow, and pain and paraesthesia may result.
Central venous lesions have to be treated, when they
are severe and disabling such in impairing upper
extremity swelling, wearisome pain or if they lead to
inadequate haemodialysis.31 If there is an underlying
cause (e.g. lymphoma, goiter, thoracic aortic aneur-
ysm, mediastinal fibrosis, pacemakers), which cannot
be treated, or where treatment fails to resolve arm
swelling, PTA with stent insertion is indicated.23In the last decade, several studies of patients treated
with PTA alone have been published. Primary patency
rates of 10% or less at 1 year and numerous restenoses
were reported.32,33 Stent implantation has been shown
to improve primary 1-year patency rates to 56% or
more30,34,35 (Fig. 3). Regular follow-up and reinterven-
tions are required to maintain patency and accomplish
long-term clinical success.34 These figures do not differ
significantly from those of surgical intervention.30,35
Nonetheless, due to the relative invasiveness of
surgery for central venous obstructions the less
invasive interventional therapy is recommended as
first-line treatment.34 Reports show that symptomatic
central venous obstruction in dialysis patients can be
treated with a high success rate through radiological
intervention.36 Stent placement should avoid overlap-
ping the ostium of a patent internal jugular vein to
achieve a safe and sufficient result, since this latter vein
is essential for future placement of central catheters.
Similarly, a stent placed in the brachiocephalic vein if
at all possible should not overlap the ostium of the
contralateral vein, otherwise contralateral stenosis
may occur and preclude future use of the contralateral
limb for access creation.
An appropriate endoprosthesis for central veins
should be flexible enough to be used in curved and
tortuous vessels. To evade stent dislocation and
proximal embolization, a self-expanding stent should
be preferred, because venous occlusions may undergo
progressive luminal enlargement after stent place-
ment. Mechanical thrombectomy should not be
regularly used as a primary therapy for dialysis-
related central venous occlusions, mostly because of
the sharp angles and slim vessel walls observed in this
region. On the other hand, thrombectomy devices are
effective tools in debulking neointimal tissue in case of
stent reocclusion. The use of thrombolytic agents inEur J Vasc Endovasc Surg Vol 32, July 2006
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primary treatment.
Central and peripheral reocclusion is a commonly
observed complication and is more likely to take place
after thrombosis has occurred for the first time.37 The
interventionalist should be ready for repeat interven-
tions, occasionally multiple, over the months and
years after the primary recanalization procedure.
Put briefly, in case of central venous occlusion
related to dialysis access, initial stent deployment is
very effective with improved long-term patency rates
compared with other therapeutic modalities such as
percutaneous balloon angioplasty alone. When inter-
ventional treatment of central venous obstruction is
impossible or fails, reassessment of patient history and
data is necessary to define the most effective surgical
method to guarantee long-term vascular access for
hemodialysis.Summary
† Adequate treatment of AV access dysfunction is a
complex undertaking in which the interventional
radiologist, vascular surgeon and nephrologist
should cooperate with each other on a conjoint
basis.
† Whilst further studies are required to determine the
most favourable and long-lasting treatment strat-
egy, a primary percutaneous treatment approach is
a cost-reducing, attractive alternative to more
invasive procedures. As long as less-invasive
equivalent therapeutic alternatives to preserve the
access are at hand and possible, the existing
vascular access should be maintained.
† In stenotic lesions and short segment thromboses
percutaneous transluminal angioplasty is the first
treatment option.
† In access thrombosis percutaneous thrombectomy
is equally successful in native fistulae and grafts.
The declotting method, whether pharmacomecha-
nical or purely mechanical, has no major effect on
short- or long-term patency. To date, either type of
method for access recanalization is suitable and
should be based on the familiarity of the inter-
ventionalist with the particular therapeutic
modality.
† Thrombosed giant aneurysms should preferably be
treated surgically.
† In case of central venous obstruction, treatment
should be performed percutaneously by PTA with
additional stent implantation, whenever possible.Eur J Vasc Endovasc Surg Vol 32, July 2006References
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